Maravai LifeSciences Holdings, Inc. $MRVI Holdings Increased by Tejara Capital Ltd

Tejara Capital Ltd grew its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 23.1% in the fourth quarter, Holdings Channel reports. The firm owned 3,020,209 shares of the company’s stock after acquiring an additional 566,768 shares during the period. Maravai LifeSciences accounts for approximately 2.3% of Tejara Capital Ltd’s holdings, making the stock its 5th largest position. Tejara Capital Ltd’s holdings in Maravai LifeSciences were worth $9,816,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Monaco Asset Management SAM increased its stake in Maravai LifeSciences by 315.0% in the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock worth $10,494,000 after buying an additional 2,775,372 shares during the period. First Eagle Investment Management LLC grew its stake in Maravai LifeSciences by 299.0% in the 4th quarter. First Eagle Investment Management LLC now owns 1,799,336 shares of the company’s stock worth $5,848,000 after acquiring an additional 1,348,405 shares in the last quarter. Royce & Associates LP grew its stake in Maravai LifeSciences by 38.0% in the 3rd quarter. Royce & Associates LP now owns 1,761,764 shares of the company’s stock worth $5,056,000 after acquiring an additional 484,908 shares in the last quarter. CenterBook Partners LP increased its position in shares of Maravai LifeSciences by 3.5% during the third quarter. CenterBook Partners LP now owns 1,691,873 shares of the company’s stock worth $4,856,000 after acquiring an additional 57,365 shares during the period. Finally, Lazard Asset Management LLC raised its stake in shares of Maravai LifeSciences by 6.2% during the third quarter. Lazard Asset Management LLC now owns 1,540,226 shares of the company’s stock valued at $4,420,000 after acquiring an additional 89,805 shares in the last quarter. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Price Performance

NASDAQ MRVI opened at $4.29 on Friday. The company has a market cap of $1.10 billion, a PE ratio of -6.04 and a beta of 0.62. The firm’s 50 day moving average price is $3.44 and its 200-day moving average price is $3.43. The company has a debt-to-equity ratio of 0.72, a quick ratio of 5.69 and a current ratio of 5.91. Maravai LifeSciences Holdings, Inc. has a 52-week low of $1.95 and a 52-week high of $4.99.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. The company had revenue of $65.84 million during the quarter, compared to the consensus estimate of $53.00 million. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. Sell-side analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.26 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on MRVI shares. Wells Fargo & Company boosted their price target on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a report on Friday, May 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $6.00 target price on shares of Maravai LifeSciences in a research report on Friday, May 8th. Wall Street Zen upgraded Maravai LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Weiss Ratings downgraded Maravai LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.